LakeShore Biopharma Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Wang Xu

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.6yrs
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO

Wang Xu (53 yo)

less than a year

Görev süresi

Mr. Wang Xu was Chief Operation Officer of LakeShore Biopharma Co. Ltd from June 4, 2024 until September 01, 2024 and serves as its Chief Executive Officer and Director since September 01, 2024. Mr. Wang h...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gang Li	Head of Marketing & Sales	1.6yrs	Veri yok	Veri yok
Yuan Liu	Head of Vaccine Research	1.6yrs	Veri yok	Veri yok
Wang Xu	CEO & Director	less than a year	Veri yok	Veri yok
Hui Shao	President	1.6yrs	Veri yok	1.64% € 907.2k
Rui Yu	CFO & Director	less than a year	Veri yok	Veri yok
Zenaida Reynoso Mojares	Chief Medical Officer	1.6yrs	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: H6Z 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Wang Xu	CEO & Director	less than a year	Veri yok	Veri yok
Hui Shao	President	1.6yrs	Veri yok	1.64% € 907.2k
Rui Yu	CFO & Director	less than a year	Veri yok	Veri yok
Dave Chenn	Chairperson of the Board	less than a year	Veri yok	Veri yok
Chunyang Shao	Independent Director	less than a year	Veri yok	Veri yok
Adam Zhao	Independent Director	less than a year	Veri yok	Veri yok
Thomas Xue	Independent Director	less than a year	Veri yok	Veri yok

0.4yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: H6Z 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

LakeShore Biopharma Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Lakeshore Biopharma Co., Ltd Announces Executive Changes

YS Biopharma Co., Ltd. Approves Board Appointments

YS Biopharma Co., Ltd. Announces Board Changes

YS Biopharma Co., Ltd. Announces Chief Executive Officer Changes

YS Biopharma Co., Ltd. Announces Management Changes

YS Biopharma Co., Ltd. Announces Appointment of New Directors

Recent updates

LakeShore Biopharma Co., Ltd Grant Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

LakeShore Biopharma Co., Ltd Provides Financial Guidance for the Half Year of Fiscal Year of 2025 and Full Year of Fiscal Year 2025 Ending on March 31, 2025

LakeShore Biopharma Co., Ltd announced delayed 20-F filing

Lakeshore Biopharma Co., Ltd Announces Executive Changes

YS Biopharma Co., Ltd. Approves Board Appointments

YS Biopharma Receives Additional 180 Day Extension from The Nasdaq Stock Market LLC to Regain Compliance with Minimum Bid Price Rule

Third quarter 2024 earnings released: EPS: CN¥1.87 (vs CN¥0.18 in 3Q 2023)

YS Biopharma Co., Ltd. Grants Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

YS Biopharma Co., Ltd. to Report Nine Months, 2024 Results on Apr 19, 2024

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of Pika Rabies Vaccine

YS Biopharma Co., Ltd. Announces Board Changes

YS Biopharma Co., Ltd. Announces Chief Executive Officer Changes

YS Biopharma Co., Ltd. Announces Management Changes

YS Biopharma Co., Ltd. Announces Appointment of New Directors

Ys Biopharma Co., Ltd. Announces Board Resignations

Second quarter 2024 earnings released: CN¥1.13 loss per share (vs CN¥0.013 profit in 2Q 2023)

YS Biopharma Co., Ltd. Appoints Rui Yu as Chairperson of Its Audit Committee, as Member of Its Compensation Committee, and as Member of the Nominating and Corporate Governance Committee

YS Biopharma Co., Ltd. Announces Board Changes

YS Biopharma Co., Ltd. Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

YS Biopharma Announces Receipt of Nasdaq Notice

YS Biopharma Co., Ltd. Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

Ys Biopharma Co., Ltd. Grants Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection

Ys Biopharma Co., Ltd. Grants Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection

New minor risk - Market cap size

YS Biopharma Co., Ltd. to Report Q2, 2023 Results on Aug 15, 2023

Full year 2023 earnings released: CN¥1.56 loss per share (vs CN¥1.72 loss in FY 2022)

YS Biopharma Co., Ltd. to Report Fiscal Year 2023 Results on Jul 26, 2023

High number of new and inexperienced directors

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş